MTOR and triple-negative breast carcinoma: In 2013, Maniscalco [83] demonstrated that m-TOR is overexpressed and activated by phosphorylation via the PI3K/AKT signaling pathway in triple negative FMC, suggesting that these tumors might be suitable models to test innovative therapies against the human triple negative breast cancers, as mTOR is considered a potential target for anti-tumor therapies (e.g., [108]).